Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Liver Histology01:27

Liver Histology

The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026
Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026
Same author

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal of hepatology·2025
Same author

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Journal of hepatology·2025
Same author

Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

The Lancet regional health. Europe·2025
Same author

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.

Lancet (London, England)·2025

Related Experiment Video

Updated: Jul 6, 2026

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

Hepatocellular carcinoma.

Josep M Llovet1, Andrew Burroughs, Jordi Bruix

  • 1Barcelona-Clínic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli;nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Lancet (London, England)
|December 12, 2003
PubMed
Summary
This summary is machine-generated.

Hepatocellular carcinoma (HCC) surveillance every 6 months aids early diagnosis in high-risk cirrhosis patients. Early detection enables curative treatments, improving survival rates for liver cancer.

More Related Videos

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Related Experiment Videos

Last Updated: Jul 6, 2026

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
12:06

Isolation of CD133+ Liver Stem Cells for Clonal Expansion

Published on: October 10, 2011

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Area of Science:

  • Hepatology
  • Oncology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) is a major global cancer with rising incidence.
  • Hepatitis B and C virus infections are key drivers of HCC.
  • Cirrhosis patients face the highest risk and require regular monitoring.

Purpose of the Study:

  • To review current management strategies for Hepatocellular Carcinoma (HCC).
  • To highlight the importance of early diagnosis and treatment options for HCC.
  • To assess the efficacy of palliative treatments for advanced HCC.

Main Methods:

  • Review of treatment outcomes for HCC.
  • Analysis of 63 randomized controlled trials on palliative HCC treatments.
  • Meta-analysis of chemoembolisation efficacy in unresectable HCC.

Main Results:

  • Surveillance every 6 months can lead to early HCC diagnosis.
  • Curative treatments (resection, transplantation) are applicable to 30% of patients in Western countries and Japan, yielding >50% 5-year survival.
  • Chemoembolisation is the only palliative treatment shown to improve survival in selected unresectable HCC patients.

Conclusions:

  • Early detection through surveillance is crucial for improving HCC outcomes.
  • Liver transplantation, while effective, is limited by donor availability.
  • Chemoembolisation offers a survival benefit for specific unresectable HCC cases.